Biogen

In News

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus - Biogen

Biogen - Jun 01, 2026

Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline - Yahoo Finance

Yahoo Finance - Jun 02, 2026

Biogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims - Fierce Pharma

Fierce Pharma - May 27, 2026

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease - Biogen

Biogen - May 21, 2026

Italy probes Biogen for allegedly hindering sales of rival's MS drug - Reuters

Reuters - May 27, 2026

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease - Biogen

Biogen - May 14, 2026

Biogen Completes Acquisition of Apellis Pharmaceuticals - Biogen

Biogen - May 14, 2026

Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch

MarketWatch - Jun 01, 2026

Lancet publication adds weight to UCB and Biogen lupus drug case - The Pharma Letter

The Pharma Letter - Jun 01, 2026

Biogen to advance experimental Alzheimer's drug despite mid-stage trial miss - Reuters

Reuters - May 14, 2026

Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times

Ophthalmology Times - May 18, 2026

Biogen axes Denali-partnered Parkinson’s drug after phase 2 flop - Fierce Biotech

Fierce Biotech - May 22, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment